Extragenital cutaneous
warts are benign epidermal
tumors caused by human papillomaviruses (HPVs) and a frequent reason for patients to consult a dermatologist. Depending on
wart type and site involved, the clinical presentation is highly varied. Given that
warts represent a self-limiting condition, a wait-and-see approach may be justified. However, treatment is always indicated if the lesions become painful or give rise to psychological discomfort. Factors to be considered in this context include subjective disease burden, patient age, site affected, as well as the number and duration of lesions. Destructive treatment methods involve chemical or physical removal of diseased tissue. Nondestructive methods consist of
antimitotic and
antiviral agents aimed at inhibiting viral proliferation in keratinocytes. Some of the various
immunotherapies available not only have localized but also systemic effects and are thus able to induce remission of
warts located at any distance from the injection site. Especially patients with
warts at multiple sites benefit from this form of treatment. Intralesional
immunotherapy using the
mumps-
measles-
rubella (
MMR) vaccine is a particularly promising option for the treatment of recalcitrant
warts in adult patients. For children, on the other hand, HPV vaccination is a novel and promising approach, even though it has not been approved for the treatment of cutaneous
warts. At present, there is no universally effective treatment available. Moreover, many frequently employed
therapies are currently not supported by conclusive clinical trials.